GE HealthCare Technologies Inc. research snapshot
GEHC AI stock analysis reads GE HealthCare Technologies Inc. as a scaled medical technology company whose operating momentum improved in the second quarter of 2026. On July 29, 2026 the company reported Q2 revenue of $5.3 billion with 3.5% organic growth, organic orders up 11.1% to the highest level since the spinoff, book-to-bill of 1.15x, and a record backlog of $23.9 billion, while adjusted EPS of $1.13 rose 6.6% and full-year guidance was maintained. The main drag is Patient Care Solutions, which fell 13.5% organically with negative segment EBIT, and management started a strategic review that could include a sale. At $68.02 and about $30.72 billion in market value, GEHC trades near 15.7x trailing EPS, 13.2x forward EPS, and 19.5x trailing free cash flow, with a consensus analyst target of $82.50. This page is informational research and not investment advice.
Current price
$68.02
Market cap
$30.72 billion
AI score
70 / 100
Rating
Improving medical technology franchise with record orders and backlog, but PCS drag, CFO transition, and margin recovery still to prove
Trend status
Improving technical trend, with price above the 20-day, 50-day, and 100-day moving averages and near the 200-day moving average, with RSI near 58
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | GE HealthCare sells mission-critical imaging systems, diagnostics, monitoring, visualization software, and services into hospitals and health systems, with Q2 2026 revenue of $5.3 billion and a record $23.9 billion backlog. | High |
| Moat | The moat comes from installed equipment, regulatory approvals, service contracts, hospital workflow integration, brand trust, clinical data, product breadth, and contrast media supply position rather than a pure network effect. | Medium-high |
| Management | CEO Peter Arduini has led GE HealthCare since the spinoff and management delivered record orders and a Q2 beat, but the CFO transition and the PCS strategic review add near-term execution uncertainty. | Medium |
| Financial trend | Q2 2026 revenue rose 3.5% organically, adjusted EPS rose 6.6% to $1.13, organic orders rose 11.1%, and full-year guidance was maintained, but PCS fell 13.5% and total adjusted EBIT margin fell 40 basis points to 14.2%. | High |
| Valuation | At $68.02, GEHC trades near 15.7x trailing EPS, 13.2x forward EPS, 2.8x book value, 19.5x trailing free cash flow, and 1.4x sales, a lower multiple than premium medtech but not a deep distress price. | Medium-high |
| Technical trend | Technical signals improved: price is above the 20-day, 50-day, and 100-day moving averages with RSI near 58, but remains below the 200-day moving average near $73, so the medium-term trend is not confirmed. | Medium |
| Risk level | Main risks are PCS decline and the strategic review outcome, hospital capital spending cycles, China, tariffs, inflation, supplier issues, reimbursement pressure, cybersecurity, product quality, debt, and CFO transition risk. | Medium-high |
| AI confidence | Descriptive confidence is high because official filings and multiple data sources agree. Return confidence is lower because PCS recovery, margin expansion, and multiple expansion are not guaranteed. | High data confidence |
| Investment certainty | Investment certainty is medium. GEHC has a real franchise and record backlog, but the thesis needs evidence of PCS stabilization, margin repair, and a clean CFO transition through the second half of 2026. | Medium |
GEHC AI stock forecast
The GEHC AI stock forecast uses scenario math around the $68.02 data cutoff price and the 2026 adjusted EPS guidance midpoint near $4.90. It does not claim that AI can predict a precise future stock price. The audited three-year model produced a bullish anchor near $114, a base anchor near $88, and a bearish anchor near $62 before dividends, using scenario growth rates and multiples. Analyst targets from S&P Global average $82.50 with a median near $83. These anchors are valuation scenarios, not guaranteed targets.
$105 to $118
More likely if AIS and PDx keep growing at high single digits, PCS stabilizes and the strategic review resolves favorably, Flyrcado scales toward the $500 million annual revenue target by 2028, Photonova Spectra CE marking opens Europe, and investors re-rate GEHC toward a higher-quality medtech multiple.
$82 to $92
More likely if organic revenue grows near the 3% to 4% guidance, adjusted EPS compounds in high single digits, PCS improves sequentially in the second half, debt stays manageable, and the stock holds near a mid-teens forward earnings multiple.
$58 to $66
More likely if PCS decline persists or the strategic review drags, hospital capital spending slows, China declines more than planned, tariffs and inflation are not offset by pricing, or the market assigns a lower multiple to slower medtech growth.
GEHC AI technical analysis
GEHC AI technical analysis is improving as of the August 2, 2026 cutoff. The stock closed at $68.02 on July 31, 2026 after a sharp post-earnings rebound, above the 20-day, 50-day, and 100-day moving averages but still below the 200-day moving average. StockAnalysis showed a 50-day average of $64.05, a 200-day average of $73.09, RSI of 57.79, and average 20-day volume of about 6.07 million shares. Barchart showed a 20-day average of $64.33, a 50-day average of $64.04, a 100-day average of $66.29, a 200-day average of $73.09, a 14-day RSI of 57.79, and an elevated 14-day historic volatility near 67%.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $68.02 | StockAnalysis.com close on July 31, 2026, down 2.75% on the day, used for the current market-cap and valuation math. |
| Immediate support | $64.04 to $64.33 | The 20-day and 50-day moving average zone, cited near $64.33 and $64.04 by Barchart and $64.05 by StockAnalysis. |
| Secondary support | $60.00 to $62.00 | A congestion zone between the current 50-day average and the 52-week low where short-term risk control would sit. |
| Major support | $58.75 | The cited 52-week low of $58.75 is the deepest technical floor and the main thesis-review level for the medium-term setup. |
| Near resistance | $68.84 to $70.00 | The July 31, 2026 open and the round $70 level form the first resistance area after the earnings-driven rebound. |
| Major resistance | $73.09 | The 200-day moving average near $73.09, cited by both StockAnalysis and Barchart, is the key medium-term resistance zone. |
| Moving averages | Above 20, 50, and 100-day; below 200-day | Price is above the 20-day, 50-day, and 100-day averages but still below the 200-day average near $73, which keeps the long-term trend unconfirmed. |
| Momentum | RSI 57.79, stochastic near overbought | Momentum is positive but not extreme, with a 14-day RSI near 57.8 and stochastic readings near 82, which suggests short-term extension risk. |
| Volume | About 6.07 million average 20-day shares | Volume is above normal after the earnings report, and breakouts should be confirmed by continued volume. |
| Volatility | 14-day historic volatility near 67% | Barchart showed historic volatility near 67% with a 14-day ATR of about $2.57, reflecting post-earnings price swings. |
| Invalidation | Close below $60, then below $58.75 | A sustained break under the low $60s would weaken the rebound, and a close below $58.75 would invalidate the medium-term recovery. |
GEHC AI trading strategy
The GEHC AI trading strategy below is a rules-based framework, not personalized financial advice. It combines record orders, backlog conversion, margin repair, PCS recovery, valuation, technical confirmation, and explicit invalidation levels.
Watch for GEHC to hold above the $64 to $64.30 support band, reclaim the 200-day moving average near $73.09, and then build toward the analyst target zone near $82 while Q3 results confirm backlog conversion and margin improvement.
A close below $60 should reduce confidence. A close below $58.75 would shift the setup from trend-following to thesis review.
If GEHC pulls back toward the $60 to $64 zone without a break in orders, backlog, or adjusted EPS guidance, compare the reset price with the base scenario near $88 and the bearish scenario near $62.
Do not average down only because the multiple looks lower than premium medtech. Require evidence that PCS is stabilizing and that price and cost actions are offsetting inflation and tariffs.
Track Q3 2026 results, organic orders, book-to-bill, backlog, adjusted EBIT margin, PCS revenue and margin, the PCS strategic review, China demand, tariff refunds, inflation offsets, free cash flow, debt, Intelerad and MIM integration, and the CFO search.
Lower the rating if PCS keeps falling while debt stays elevated, if the strategic review stalls without a clear path, or if margin recovery keeps moving out beyond 2026.
Investment research summary
Customers pay GE HealthCare because hospitals need reliable imaging, diagnostics, monitoring, visualization, workflow software, service, and uptime for clinical decisions and patient throughput.
The moat is strongest in installed equipment, regulated product lines, service contracts, clinical workflow integration, hospital relationships, brand trust, and contrast media supply. It is weaker where hardware replacement cycles are slow or procurement pressure is high, as shown by the PCS decline.
The thesis can fail if PCS keeps declining and the strategic review drags, hospital capital spending slows, China demand stays weak, tariffs and inflation overwhelm pricing, product quality or cybersecurity issues rise, or debt-funded acquisitions dilute returns.
Peter Arduini has medtech operating experience and has led GE HealthCare since the spinoff. The July 2026 CFO transition adds near-term uncertainty, while management is using Heartbeat, targeted M&A, buybacks, and dividends to support growth and margins.
GEHC sits in long-duration healthcare needs: imaging, diagnostics, AI-assisted workflow, cloud enterprise imaging, and hospital productivity. The trend is durable, but not immune to budget cycles, regulation, reimbursement pressure, and inflation.
At roughly 15.7x trailing EPS and 13.2x forward EPS, GEHC offers more valuation support than high-growth medtech, but the margin of safety depends on organic growth, PCS recovery, cash conversion, and a credible path back to better margins.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GEHC quote reference | $68.02 close on July 31, 2026, down 2.75% on the day | StockAnalysis.com quote page | August 2, 2026 |
| Market capitalization verification | $30.72 billion calculated from $68.02 x 451.69 million shares, matching the reported market cap | Pineify financial_rigor.py and StockAnalysis statistics | August 2, 2026 |
| Shares outstanding | 451.69 million shares, down 0.55% year over year; institutions hold about 91.6% | StockAnalysis statistics | August 2, 2026 |
| Q2 2026 revenue | $5.3 billion with 3.5% organic growth; product revenue up 4.7% and service revenue up 7.7% | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| Q2 2026 orders and backlog | Organic orders up 11.1%, book-to-bill 1.15x, and record backlog of $23.9 billion, up $2.6 billion year over year | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| Q2 2026 profit | Adjusted EPS of $1.13, up 6.6%; adjusted EBIT of $750 million with adjusted EBIT margin of 14.2%, down 40 basis points year over year; included $23 million of tariff refunds | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| Q2 2026 cash flow | Free cash flow of $68 million including $107 million of tariff refunds; about $200 million of shares repurchased during the quarter | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| FY2026 guidance | Organic sales growth of 3% to 4%, adjusted EBIT margin of 15.4% to 15.7%, adjusted EPS of $4.80 to $5.00, and free cash flow of about $1.6 billion | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| Segment performance Q2 2026 | Advanced Imaging Solutions organic revenue up 5% with EBIT margin up 90 basis points; PDx organic revenue up 14.6% with EBIT margin of 29.6%; PCS organic revenue down 13.5% with negative EBIT | GE HealthCare Q2 2026 earnings call, July 29, 2026 | August 2, 2026 |
| TTM financials | TTM revenue of $21.27 billion, TTM net income of $1.99 billion, TTM EPS of $4.34, and TTM free cash flow of $1.58 billion | StockAnalysis statistics and financials pages | August 2, 2026 |
| Cash and debt | $2.08 billion cash and equivalents, $10.54 billion total debt, and net cash of negative $8.46 billion | StockAnalysis statistics | August 2, 2026 |
| Valuation ratios | PE 15.67, forward PE 13.15, PS 1.44, PB 2.80, P/FCF 19.46, EV/EBITDA 11.73, and PEG 1.51 | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Average price target of $82.50 with consensus Buy from 19 analysts; low $70, median $83, and high $96 | S&P Global via StockAnalysis forecast page | August 2, 2026 |
| Technical indicators | StockAnalysis showed 50-day average $64.05, 200-day average $73.09, RSI 57.79, and average 20-day volume 6.07 million shares | StockAnalysis statistics | August 2, 2026 |
| Additional technical snapshot | Barchart showed 20-day average $64.33, 50-day $64.04, 100-day $66.29, 200-day $73.09, 14-day RSI 57.79, and 14-day historic volatility near 67% | Barchart technical analysis | August 2, 2026 |
This GEHC AI stock analysis page is an informational research tool only. It is not investment advice, financial planning, or a recommendation to buy, sell, short, or hold GE HealthCare Technologies Inc. Forecast scenarios are based on available public data and simplified assumptions as of August 2, 2026, and they can be wrong. Always verify current filings, prices, liquidity, tax rules, and personal risk constraints before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
